Madopar Hbs

Levodopa/Benserazide, the active ingredient in Madopar Hbs, is a dopamine precursor and aromatic L‑amino acid decarboxylase inhibitor presented as an oral tablet for oral administration. It is used to manage Parkinson's disease and Parkinsonian syndromes by compensating for dopamine deficiency in the central nervous system.

GNH USA supplies Madopar Hbs as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution aligned to EU regulatory standards. The company ensures product integrity through controlled shipping and documentation for global procurement.

Madopar Hbs is indicated for the treatment of Parkinsonian disorders, where restoration of dopaminergic activity is required.

- Parkinson's disease: improves motor symptoms such as bradykinesia, rigidity and tremor. - Parkinsonian syndrome: alleviates motor dysfunction caused by dopamine deficiency. - Secondary Parkinsonism: provides symptomatic relief when dopamine pathways are impaired. - Fluctuating Parkinsonian symptoms: reduces OFF periods and enhances ON time during the day.

Levodopa/Benserazide may cause a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects: - Nausea: upset stomach often occurring at treatment initiation. - Vomiting: may accompany nausea, especially with rapid dose escalation. - Dizziness or light‑headedness: related to orthostatic blood pressure changes. - Headache: mild to moderate intensity, usually transient. - Insomnia: difficulty falling or staying asleep. - Orthostatic hypotension: drop in blood pressure upon standing.

Serious or Rare Side Effects: - Dyskinesia: involuntary, erratic movements that can be disabling. - Hallucinations or psychosis: visual disturbances or altered perception. - Severe hypotension: marked drop in blood pressure leading to fainting. - Neuroleptic malignant syndrome: rare but life‑threatening reaction. - Cardiac arrhythmias: irregular heart rhythms observed in susceptible patients.

When prescribing Madopar Hbs, clinicians should consider several safety measures to optimize benefit and reduce risk.

- Dose titration: start with the lowest effective dose and increase gradually to minimize adverse effects. - Renal and hepatic function: assess before initiation and adjust in impairment. - Cardiovascular status: monitor for hypotension, especially in patients with pre‑existing heart disease. - Pregnancy and lactation: safety not established; use only if potential benefit justifies the risk. - Concomitant antipsychotics: may diminish therapeutic effect and increase motor complications. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original container.

Madopar Hbs can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: may cause hypertensive crisis when combined. - Antipsychotics (e.g., haloperidol, risperidone): can block dopaminergic action and reduce effectiveness. - Iron or calcium supplements: decrease levodopa absorption from the gastrointestinal tract.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: additive blood‑pressure‑lowering effect may require dose adjustment. - Selective MAO‑B inhibitors (e.g., selegiline, rasagiline): can increase levodopa plasma concentrations and risk of side effects.